公开(公告)号：US20240293353A1

公开(公告)日：2024-09-05

申请号：US18491524

申请日：2023-10-20

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan GLICKLICH

IPC: A61K31/325 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/33 ,  A61P9/12

CPC classification number: A61K31/325 ,  A61K31/33 ,  A61P9/12 ,  A61K9/148 ,  A61K9/20 ,  A61K9/48

Abstract: Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

公开(公告)号：US20240108616A1

公开(公告)日：2024-04-04

申请号：US18506606

申请日：2023-11-10

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC classification number: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US11766412B2

公开(公告)日：2023-09-26

申请号：US16334256

申请日：2017-09-26

Applicant: GENEHEAL BIOTECHNOLOGY CO., LTD.

Inventor： Wuguang Pan ,  Wei Zhu

IPC: A61K31/132 ,  A61K31/155 ,  A61K38/05 ,  A61K38/06 ,  A61P25/00 ,  A61P35/00 ,  A61K31/661 ,  A61K31/513 ,  A61K31/198 ,  A61K31/7076 ,  A61K31/675 ,  A61K31/415 ,  A61K31/4402 ,  A61K31/197 ,  A61K31/4188 ,  A61K31/708 ,  C07D213/66 ,  C07D213/77 ,  C07D405/04 ,  C07D401/04 ,  A61K31/43 ,  A61P3/00 ,  C07D261/04 ,  C07D207/12 ,  A61P25/14 ,  A61K31/33 ,  C07D473/34 ,  A61K38/07 ,  A61K31/397 ,  A61K31/7072 ,  A61P25/08 ,  A61K31/40 ,  A61P43/00 ,  A61K31/435

CPC classification number: A61K31/155 ,  A61K31/132 ,  A61K31/197 ,  A61K31/198 ,  A61K31/33 ,  A61K31/397 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/43 ,  A61K31/435 ,  A61K31/4402 ,  A61K31/513 ,  A61K31/661 ,  A61K31/675 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/05 ,  A61K38/06 ,  A61K38/063 ,  A61K38/07 ,  A61P3/00 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P35/00 ,  A61P43/00 ,  C07D207/12 ,  C07D213/66 ,  C07D213/77 ,  C07D261/04 ,  C07D401/04 ,  C07D405/04 ,  C07D473/34

Abstract: Provided are compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capable of effectively interfering with PAICS activity, reducing SAICAR synthesis, and ultimately reducing SAICAR accumulation, in order to achieve the goal of treating or improving ADSL deficiency. A better effect in the treatment or improvement of ADSL deficiency is expected from the joint use of at least two of the described compounds.

公开(公告)号：US20230226045A1

公开(公告)日：2023-07-20

申请号：US18157680

申请日：2023-01-20

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC classification number: A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US20220193015A1

公开(公告)日：2022-06-23

申请号：US17562787

申请日：2021-12-27

Applicant: Jazz Pharmaceuticals Ireland Limited

Inventor： Mark ELLER

IPC: A61K31/19 ,  A61K31/20 ,  A61P11/00 ,  A61P25/20 ,  A61P43/00 ,  A61K31/616 ,  A61K31/33 ,  A61K31/505 ,  A61K31/55

Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.

公开(公告)号：US11033536B2

公开(公告)日：2021-06-15

申请号：US16451781

申请日：2019-06-25

Applicant: CENTRE FOR DIGESTIVE DISEASES

Inventor： Thomas Julius Borody

IPC: A61K31/44 ,  A61K31/43 ,  A61K31/33 ,  A61K31/4439 ,  A61P31/04 ,  A61K31/4178 ,  A61K31/424 ,  A61K31/426 ,  A61K31/438 ,  A61K31/5383 ,  A61K31/65 ,  A61K33/245

Abstract: Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.

公开(公告)号：US20210147379A1

公开(公告)日：2021-05-20

申请号：US17251289

申请日：2019-06-14

Applicant: University of Florda Research Foundation,Incorporated

Inventor： Brian Keith Law ,  Ronald K. Castrllao

IPC: C07D339/08 ,  C07D345/00 ,  C07D339/04 ,  C07D339/00 ,  A61K45/06 ,  A61K31/33 ,  A61K31/385 ,  A61P35/00

Abstract: The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.

公开(公告)号：US10894774B2

公开(公告)日：2021-01-19

申请号：US15498856

申请日：2017-04-27

Applicant: FibroGen, Inc.

Inventor： Stephen J. Klaus ,  Christopher J Molineaux ,  Thomas B Neff ,  Volkmar Guenzler-Pukall ,  Robert C. Stephenson ,  Todd W. Seeley ,  Ingrid Langsetmo Parobok

IPC: A61K31/33 ,  A01N43/00 ,  C07D213/00 ,  C07D217/24 ,  A61K31/00 ,  A61K31/165 ,  A61K31/395 ,  C07C275/40 ,  A61K31/472 ,  A61K31/17

Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.

公开(公告)号：US20200268885A1

公开(公告)日：2020-08-27

申请号：US16807298

申请日：2020-03-03

Applicant: POLYTHERICS LIMITED

Inventor： Antony Godwin ,  Mark Frigerio

IPC: A61K47/10 ,  A61K47/60 ,  A61K47/68 ,  A61K31/33

Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W′ represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.

公开(公告)号：US10722483B2

公开(公告)日：2020-07-28

申请号：US16420465

申请日：2019-05-23

Applicant: CymaBay Therapeutics, Inc.

Inventor： Brian Roberts ,  Xueyan Wang ,  Yun-Jung Choi ,  David Karpf ,  Robert Martin ,  Charles McWherter

IPC: A61K31/192 ,  A61K31/33 ,  A61K9/00

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.